KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Depreciation & Amortization (CF) (2020 - 2025)

Recursion Pharmaceuticals (RXRX) has disclosed Depreciation & Amortization (CF) for 6 consecutive years, with $19.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Depreciation & Amortization (CF) rose 50.4% year-over-year to $19.5 million, compared with a TTM value of $83.7 million through Dec 2025, up 129.36%, and an annual FY2025 reading of $83.7 million, up 129.36% over the prior year.
  • Depreciation & Amortization (CF) was $19.5 million for Q4 2025 at Recursion Pharmaceuticals, down from $21.0 million in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $23.8 million in Q2 2025 and bottomed at $1.4 million in Q1 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $8.2 million, with a median of $6.4 million recorded in 2023.
  • The sharpest move saw Depreciation & Amortization (CF) dropped 5.01% in 2024, then surged 192.35% in 2025.
  • Year by year, Depreciation & Amortization (CF) stood at $2.2 million in 2021, then skyrocketed by 43.74% to $3.2 million in 2022, then skyrocketed by 135.0% to $7.6 million in 2023, then skyrocketed by 71.47% to $13.0 million in 2024, then surged by 50.4% to $19.5 million in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for RXRX at $19.5 million in Q4 2025, $21.0 million in Q3 2025, and $23.8 million in Q2 2025.